WINTON GROUP Ltd Sells 56,799 Shares of Gilead Sciences, Inc. $GILD

WINTON GROUP Ltd trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 85.1% during the fourth quarter, HoldingsChannel.com reports. The fund owned 9,943 shares of the biopharmaceutical company’s stock after selling 56,799 shares during the quarter. WINTON GROUP Ltd’s holdings in Gilead Sciences were worth $1,220,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Ares Financial Consulting LLC bought a new stake in Gilead Sciences in the fourth quarter valued at $28,000. Financial Consulate Inc. grew its position in Gilead Sciences by 85.8% in the fourth quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 109 shares during the period. North Star Investment Management Corp. grew its position in Gilead Sciences by 54.8% in the fourth quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 86 shares during the period. BOCHK Asset Management Ltd bought a new stake in Gilead Sciences in the fourth quarter valued at $31,000. Finally, Godfrey Financial Associates Inc. bought a new stake in Gilead Sciences in the fourth quarter valued at $34,000. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $128.10 on Tuesday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. The firm has a market cap of $159.05 billion, a P/E ratio of 17.45 and a beta of 0.31. The business’s fifty day moving average is $134.20 and its two-hundred day moving average is $134.39. Gilead Sciences, Inc. has a 52 week low of $104.46 and a 52 week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. The company had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The business’s revenue was up 4.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Equities research analysts forecast that Gilead Sciences, Inc. will post -0.79 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be issued a $0.82 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.6%. Gilead Sciences’s dividend payout ratio (DPR) is currently 44.69%.

Insider Activity at Gilead Sciences

In related news, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $131.29, for a total value of $3,676,120.00. Following the completion of the sale, the insider owned 125,779 shares of the company’s stock, valued at $16,513,524.91. This trade represents a 18.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $132.27, for a total transaction of $396,810.00. Following the completion of the sale, the chief financial officer directly owned 173,191 shares of the company’s stock, valued at approximately $22,907,973.57. This represents a 1.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 68,000 shares of company stock valued at $9,047,570 over the last quarter. Corporate insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

GILD has been the topic of a number of analyst reports. Deutsche Bank Aktiengesellschaft upped their price target on Gilead Sciences from $135.00 to $155.00 and gave the company a “buy” rating in a research report on Wednesday, February 11th. Royal Bank Of Canada reaffirmed a “sector perform” rating on shares of Gilead Sciences in a report on Monday. Scotiabank raised their price objective on shares of Gilead Sciences from $140.00 to $177.00 and gave the stock a “sector outperform” rating in a report on Wednesday, February 11th. JPMorgan Chase & Co. raised their price objective on shares of Gilead Sciences from $150.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday, February 11th. Finally, Morgan Stanley dropped their price objective on shares of Gilead Sciences from $175.00 to $168.00 in a report on Friday, May 8th. Twenty-five research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $156.93.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.